These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2039760)

  • 1. Dopamine and norepinephrine activity in schizophrenia. An integrative perspective.
    van Kammen DP; Kelley M
    Schizophr Res; 1991; 4(2):173-91. PubMed ID: 2039760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis.
    van Kammen DP
    Psychol Med; 1991 Nov; 21(4):881-95. PubMed ID: 1685791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for reduced and dysregulated turnover of dopamine in schizophrenia.
    Heritch AJ
    Schizophr Bull; 1990; 16(4):605-15. PubMed ID: 2077638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired noradrenergic transmission in schizophrenia?
    van Kammen DP; Antelman S
    Life Sci; 1984 Apr; 34(15):1403-13. PubMed ID: 6323903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NE/DA interactions in prefrontal cortex and their possible roles as neuromodulators in schizophrenia.
    Tassin JP
    J Neural Transm Suppl; 1992; 36():135-62. PubMed ID: 1356142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological markers in schizophrenia].
    Lembreghts M; Ansseau M
    Encephale; 1993; 19(5):501-23. PubMed ID: 8306920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated thalamic dopamine: possible link to sensory dysfunctions in schizophrenia.
    Oke AF; Adams RN
    Schizophr Bull; 1987; 13(4):589-604. PubMed ID: 2830663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensory physiology and catecholamines in schizophrenia and mania.
    Adler LE; Gerhardt GA; Franks R; Baker N; Nagamoto H; Drebing C; Freedman R
    Psychiatry Res; 1990 Mar; 31(3):297-309. PubMed ID: 2333360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacology of antipsychotic drugs]].
    Bourin M
    Encephale; 2006 Jan; 32 Pt 2():S8-9. PubMed ID: 16800078
    [No Abstract]   [Full Text] [Related]  

  • 10. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
    Dépatie L; Lal S
    J Psychiatry Neurosci; 2001 May; 26(3):203-20. PubMed ID: 11394190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A theory of dopamine function and its role in cognitive deficits in schizophrenia.
    Cohen JD; Servan-Schreiber D
    Schizophr Bull; 1993; 19(1):85-104. PubMed ID: 8095737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
    Amin F; Davidson M; Kahn RS; Schmeidler J; Stern R; Knott PJ; Apter S
    Schizophr Bull; 1995; 21(1):53-66. PubMed ID: 7770741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathways to schizophrenia: the impact of environmental factors.
    Howes OD; McDonald C; Cannon M; Arseneault L; Boydell J; Murray RM
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S7-S13. PubMed ID: 14972079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine.
    Joyce JN
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S16-34. PubMed ID: 7831438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic antecedents of dopamine dysfunction in schizophrenia.
    Amin F; Silverman JM; Siever LJ; Smith CJ; Knott PJ; Davis KL
    Biol Psychiatry; 1999 May; 45(9):1143-50. PubMed ID: 10331106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic strategies for augmenting cognitive performance in schizophrenia.
    Friedman JI; Temporini H; Davis KL
    Biol Psychiatry; 1999 Jan; 45(1):1-16. PubMed ID: 9894570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
    Masana M; Bortolozzi A; Artigas F
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):53-68. PubMed ID: 20701825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine in schizophrenia: a review and reconceptualization.
    Davis KL; Kahn RS; Ko G; Davidson M
    Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Deficit schizophrenia: from pharmacology to clinical practice].
    Tassin JP
    Encephale; 1996 Jun; 22 Spec No 2():9-12. PubMed ID: 8767035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Integrative Perspective on the Role of Dopamine in Schizophrenia.
    Maia TV; Frank MJ
    Biol Psychiatry; 2017 Jan; 81(1):52-66. PubMed ID: 27452791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.